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Background.Theevent-freesurvival forpediatricleukemiainlow-incomeCountriesismuchlower thaninhigh-incomecountries.
Late diagnosis, which is regarded as a contributing factor, may be due to “parental” or “medical” delay. Procedures. The present
study analyses determinants of lag time from ﬁrst symptoms to diagnosis of leukemia, comparing pediatric (0–16 years old)
patients in two referral centers, one in Nicaragua and one in Italy. An observational retrospective study was conducted to assess
factors inﬂuencing the time to diagnosis. Results. 81 charts of children diagnosed with acute myeloid leukemia or lymphoblastic
leukemia were analyzed from each centre. Median lag time to diagnosis was higher in Nicaragua than in Italy (29 versus 14 days,
P<0.001) and it was mainly due to “physician delay” (16.5 versus 7 days, P<0.001), whereas “patient delay” from symptoms to
ﬁrst medical assessment was similar in the two centers (7 versus 5 days, P = 0.27). Moreover, median lag time from symptoms to
diagnosis was decreased in Nicaraguan districts were a speciﬁc training program upon childhood oncological diseases was carried
out (20.5 versus 40 days, P = 0.0019). Conclusions. Our study shows that delay in diagnosis of childhood leukemia is mainly
associated with “physician delay” and it may be overcome by programs of continuous medical education.
1.Introduction
Childhood leukemia is the most common childhood cancer,
with an annual incidence of 4.5:100.000 [1]. The most
common leukemia subtype is acute lymphoblastic leukemia
(ALL) and the majority of aﬀected patients (80%, 75.000
cases/year) live in low income countries (LIC). There, the
e s t i m a t e d5y e a r se v e n t - f r e es u r v i v a l( E F S )i so n l y3 5 % ,v e r -
sus 75% in high income countries (HIC), due to diﬃculties
in diagnosing and treating the disease or inadequate medical
facilities and to socioeconomical factors [2–5]. Few studies
haveanalyzedthedeterminantsoflagtimeinthediagnosisof
childhood cancer or leukemia [6–15]. Very few studies have
been conducted to assess the impact of “medical delay” on
timingofcancerdiagnosisandonlyoneresearchonleukemia
in LIC is available to our knowledge [15].
The present study reports the lag time from ﬁrst symp-
toms to diagnosis in childhood leukemia in the Referral
Center of Nicaragua. The impact of physicians’ delay is
analyzed and is compared with that of an HIC Center.
2.MaterialsandMethods
The study (observational, retrospective) was run in the con-
text of a twinning program for pediatric hematooncology
started in 1986 between La Mascota Hospital in Managua
(Nicaragua)andSanGerardoHospitalinMonza(Italy)[16].
Eligible for the study at “La Mascota Hospital” were
all children under 16 years of age who were diagnosed
with acute myeloid leukemia (AML) or acute lymphoblastic
leukemia (ALL) (n = 81) between August 2006 and
January 2009. Data were obtained from medical records and2 International Journal of Pediatrics
veriﬁed through semistructured interviews with one or both
parents. Interviews were conducted by the same physician
and took place within 12 months after the diagnosis in the
majority (90%) of cases. The pathway from ﬁrst symptoms
to diagnosis was analyzed considering the following items:
type of medical structures where the ﬁrst assessment took
place and number of medical evaluations, laboratory or
imaging investigations, and treatments performed before the
diagnosis. Age, gender, number of family members, family
daily income, “parents’ education level,” distance from the
referralcentre(hoursoftravel),districtoforigin,andclinical
condition at admission were also considered.
A comparison group of Italian children (n = 81) diag-
nosed with ALL or AML between August 2006 and June 2009
at San Gerardo Hospital in Monza was used to assess the
impact of “patient” (see below) and “physician” delay in the
two countries (Nicaragua and Italy). Data was collected from
medical records where information about history from ﬁrst
symptoms to diagnosis are regularly collected interviewing
parents at ﬁrst admission for clinical research purposes.
Selection criteria for this comparison group were the
sameappliedinthestudygroup:81consecutivepatientswho
underwent treatment or clinical assessment in the outpatient
clinic.
The time interval from ﬁrst symptoms to diagnosis was
deﬁned as “lag time” and classiﬁed as follows: “patient delay”
and “physician delay.” The former was deﬁned as the time
interval from ﬁrst symptoms to ﬁrst medical consultation,
the latter as the time interval from ﬁrst consultation to diag-
nosis [17]. The word “delay” was meant as a time interval,
measured in days, without implying whether this interval
exceeded a particular threshold of clinical acceptability. Lag
time in the population was divided into two time intervals:
“0–30 days” and “>30 days” to compare our results with
published data.
The type of ﬁrst medical evaluation was classiﬁed into
3 levels: “ﬁrst” (private doctor, primary healthcare services),
“second” (private and public hospitals), and “third” (referral
centers:LaMascotaHospitalinManagua,NicaraguaandSan
Gerardo Hospital in Monza, Italy).
Clinical conditions at admission were described as
“poor” in presence of mucosal hemorrhagic diathesis, sepsis
or need for oxygen therapy; in “good” conditions otherwise.
Nicaraguan patients population was divided into two
subgroups using median age as cutoﬀ:“ <7y e a r so l d ”o r“ ≥7
and ≤16 years old”.
Nicaraguan national districts were classiﬁed in two cat-
egories: “qualiﬁed” (districts where a speciﬁc training pro-
gram in pediatric oncology was carried out) and “not quali-
ﬁed”.
2.1. Statistical Analysis. Statistical analysis was performed
with the EPI INFO software. Correlation between diﬀerent
variables was examined with the chi-square test (P signif-
icance of 0.05). In case of a small sample (n<5), the
Fisher exact test was used. Nonparametric tests (Mann-
Whitney/Wilcoxon Two-Sample Test) was used to determine




































Figure 1: Lag time to diagnosis in days: cumulative percentage.
3. Results
This study included 81 children with leukemia (age 0 to 16
years)frombothLaMascotaHospital,Managua(Nicaragua)
and San Gerardo Hospital, Monza (Italy). Median age was
7.25 years in the Nicaraguan population and 6.4 years in the
Italian one. Males were 41 in Nicaraguan sample and 48 in
the Italian one. ALL or AML was diagnosed, respectively,
in 76 and 5 Nicaraguan children and in 70 and 11 Italian
patients.
Data concerning the time interval from ﬁrst symptoms
to diagnosis and the diagnostic pathway are shown in Tables
1 and 2. Median lag time in Managua was greater than
in Monza (29 versus 14 days, P<0.01). “Patient delay”
was similar for Nicaraguan and Italian populations (median:
7v e r s u s5d a y s ,P = 0.27), while “physician delay” was
signiﬁcantly greater in Nicaraguan sample (median: 16.5
versus 7 days, P<0.01). Results were similar when ALL and
AML subgroups were analyzed separately (Table 1).
Overall the percentage of cases diagnosed >30 days after
the onset of symptoms was signiﬁcantly higher in Managua
(45.7% versus 18.5%, P<0.01) (Table 1 and Figure 1).
Nicaraguan patients who came from “qualiﬁed districts”
were diagnosed within a shorter lag time than those from the
remainingdistricts(medianlagtime:20,5versus40days,P<
0.01 Mann-Whitney/Wilcoxon test).
There was a higher percentage of Nicaraguan children
with poor condition at admission compared to Italian ones
(P = 0.013). In both populations the most frequent ﬁrst
medical aid was given at a primary healthcare facility.
However Nicaraguan patients were checked more times (P<
0.01) and more frequently received medical treatment such
as antibiotic therapies (P = 0.04) and iron supplementation
(P<0.01) before diagnosing leukemia (Table 2).
Age was associated with lag time: younger patients (<7
yearsold)hadhigherprobabilitiesofbeingdiagnosedatleast
30 days after the onset of ﬁrst symptoms compared to the
older ones (57% versus 33%, P = 0.03, Chi-square test).International Journal of Pediatrics 3
Table 1: Time intervals from ﬁrst symptoms to diagnosis of leukemia.
Managua Monza P value
Lag time from ﬁrst symptoms to diagnosis (days)
Median, (IQR) 29 (18–44) 14 (9–24) #P<0.01
ALL 29,5 (18–45) 15 (9–27) #P<0.01
AML 21 (18–39) 9 (6–20) #P = 0.03
Patient delay (days)
Median, (IQR) 7 (1,5–15) 5 (1–13) #P = 0.27
ALL 7 (1,5–15) 5,5 (1–13) #P = 0.5
AML 6 (3–11) 4 (2–13) #P = 0.9
Physician delay (days)
Median, (IQR) 16.5 (7–33,5) 7 (2–4) #P<0.01
ALL 16 (7–33) 8 (2–15) #P<0.01
AML 18 (6–33) 3 (1–6) #P = 0.03
Lag time to diagnosis: “0–30 days” and “>30 days” groups
Lag time to diagnosis “>30 days” (frequencies) 37 (45.7%) 15 (18.5%) ◦P<0.01
Lag time to diagnosis “0–30 days” (frequencies) 44 (54.3%) 66 (81.5%)
◦: Chi-square test; #: Mann-Whitney/Wilcoxon Two-Sample Test; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia.
Table 2: Medical assessments performed before diagnosing leukemia and clinical condition at the diagnosis.
Managua Monza P value
Number of medical evaluations before diagnosis
Median, (IQR) 3 (2–4) 2 (2-3) #P<0.01
Clinical conditions at admission (frequencies)
Good 52 (64.2%) 71 (87.7%) ◦P = 0.013
Poor 29 (35.8%) 10 (12.3%)
Type of ﬁrst medical evaluation before diagnosis (frequencies)
First 51 (63%) 57 (70.4%) ◦P = 0.32
Second 29 (35.8%) 23 (28.4%) ◦P = 0.31
Third 1 (1.2%) 1 (1.2%) •P = 0.75
Antibiotics treatment before diagnosis (frequencies)
Yes 48 (59%) 35 (43%) ◦P = 0.04
No 33 (41%) 46 (57%)
Iron supplementation before diagnosis (frequencies)
Yes 16 (20%) 0 (0%) •P<0.01
No 65 (80%) 81 (100%)
◦: Chi-square test; •: Fisher Test; #: Mann-Whitney/Wilcoxon Two-Sample Test.
4. Discussion
Leukemiaisoneoftheleadingcausesofdisease-relateddeath
in children living in HIC, but it represents an important
public health concern also in LIC, where diﬃculties in
diagnosing and treating childhood malignancies undermine
the outcome (5 years EFS 75% versus 35% in HIC at
LIC, respectively, [2–4]). Delay in diagnosis could be a
contributing factor in this context.
In our study we found that median lag time from the
ﬁrst symptoms to diagnosis of childhood leukemia in La
Mascota Hospital, Managua—Nicaragua was signiﬁcantly
higher than in San Gerardo Hospital, Monza, Italy (29 versus
14 days, P<0, 001) with a signiﬁcantly higher percentage of
Nicaraguan patients diagnosed after >30 days compared to
Italian ones (45,7% versus 18,5%) (Figure 1). This delay may
be a contributing factor to the worse clinical conditions at
admission of Nicaraguan children compared to Italian ones
(P = 0.013), although the worse health status of childhood
population in Nicaragua has also to be taken into account
[18].
These results are consistent with data already reported in
the literature [8]( Table 3), which describe a median lag time
to diagnosis for leukemia of 2 weeks in HIC and 4 weeks in
LIC [17].
We therefore analyzed lag time composition: median
“patient delay” (5 versus 7 days) does not diﬀer in the
two countries and is comparable to data available for HIC
(Table 3); “physician delay” is on the other hand higher in
Nicaragua compared to Italy. Data collected in Nicaragua are4 International Journal of Pediatrics
Table 3: Literature notes about studies dealing with lag time from ﬁrst symptoms to diagnosis in childhood leukemia.
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Klein Geltink et al.
[10]C a n a d a 7 (1–19) 1 (0–11) NA∗ NA∗ 826 patients aged
0–15 (1995–2000)
Thulesius et al.
[12]S w e d e n 7 (0–91) 0 (0–63) 21 (0–105) 24% 25 patients aged







Saha et al. [11]
United Kingdom NA∗ NA∗ 21 (7–224) NA∗ 65 patients aged
0–15 (1982–1990)
Flores et al. [9]
U.S.A. NA∗ NA∗ NA∗ 18,7% 123 patients aged
0-20 (1976–1984)
Dang-Tan et al. [6]
Canada 8 (1–21) 3 (1–14) 19 (9–36) NA∗ 944 patients aged
0–19 (1995–2000)
De Angelis et al.
(this paper) Italy 5 (1–13) 7 (2–4) 16.5 (7–33,5) 18,5% 81 patients aged
0–16 (2006–2009)
Fajardo-Guti´ errez
et al. [8] Mexico NA∗ NA∗ NA∗ 47% 1676 patients aged
0–14 (1981–1992)
LIC
James BO et al.
[14] Nigeria NA∗ NA∗ 56 (14–252) NA∗ 9 patients aged
1–14 (2006–2008)
Stefan et al. [15]
South Africa 4( N A ∗)2 2 ( N A ∗)3 1 ( N A ∗)N A ∗ 63 patients aged
0–15 (2000–2009)




(7–33,5) 29 (18–44) 45,7% 81 patients aged
0–16 (2006–2009)
∗NA: not available.
similar to the results reported by Stefan et al. from an urban
area of South Africa [15].
“Physician lag time” for Nicaraguan patients was higher
despite the higher frequency of medical examinations and
prescriptions.
This may be due to a diﬀerent medical expertise towards
oncologic diseases in childhood and to confounding symp-
toms of common infectious diseases [19–22].
Ofimportance,thesocioeconomicparameters,whichare
known to play an important role on prognosis in Nicaragua
[23–26], did not inﬂuence lag time to diagnosis in our study.
The present study also shows that Nicaraguan children <7
years old were diagnosed with a greater lag time than the
older ones (up to 16 years of age). These data are interesting
because, in presence of a signiﬁcant correlation with age, the
opposite has been reported for childhood solid tumors both
in LIC and in HIC [6, 8–11]. This could be due to older
patients’abilitytobetterdescribespeciﬁcsymptomsortothe
lack of regular medical care for younger children.
Otherauthorsfoundacorrelationbetweendistancefrom
referral centre and lag time, both in HIC and in LIC [8, 10].
In our study the distance from Managua did not inﬂuence
the time to diagnosis, but there was a signiﬁcant diﬀerence
in lag time according to the district of origin. Nicaraguan
patients from “qualiﬁed districts” were diagnosed earlier
than those from the remaining districts. This data underlines
the importance of speciﬁc training programs in childhood
cancer for physicians working in ﬁrst or second level health
care centers.
Unfortunately we do not have yet data about correlation
between “lag time to diagnosis” and Event Free Survival
(EFS) rate in Nicaragua; for this reason the potential impact
of our ﬁndings on outcome has still to be determined and
should be investigated in the future.
5. Conclusions
In conclusion, this study, although based on relatively small
samples, shows that lag time from ﬁrst symptoms to child-
hood leukemia diagnosis is signiﬁcantly greater in patients
admitted at “La Mascota Hospital” (Managua, Nicaragua)
compared to those admitted at “San Gerardo Hospital”
(Monza,Italy);thelagtimeismostlydueto“physiciandelay.”
Diagnosis delay in LIC may be inﬂuenced by the fact that
symptoms of leukemia at the onset might resemble other
diseases which have a high prevalence in these countries (i.e.,
infectious diseases, anemia, and malnutrition). Lag time in
Nicaragua seems to be associated to a low suspicion of the
oncologicdiseasethatmaybeimprovedbyspeciﬁcprograms
formedicaltraininginﬁrstlevelhealthcarecenters.Thusthe
present study suggests that speciﬁc educational programs for
physicians may be the most important mean to decrease the
diagnostic lag time for childhood leukemia in LIC.International Journal of Pediatrics 5
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